1. Home
  2. SHMD vs NGNE Comparison

SHMD vs NGNE Comparison

Compare SHMD & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCHMID Group N.V. Class A Ordinary Shares

SHMD

SCHMID Group N.V. Class A Ordinary Shares

HOLD

Current Price

$8.96

Market Cap

323.0M

Sector

N/A

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$18.73

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHMD
NGNE
Founded
1864
2003
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
323.0M
327.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SHMD
NGNE
Price
$8.96
$18.73
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$40.14
AVG Volume (30 Days)
496.3K
152.7K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$85,165,542.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.86
$6.88
52 Week High
$9.98
$37.27

Technical Indicators

Market Signals
Indicator
SHMD
NGNE
Relative Strength Index (RSI) 63.81 47.33
Support Level $7.59 $18.12
Resistance Level $9.98 $20.44
Average True Range (ATR) 1.05 1.23
MACD -0.02 0.25
Stochastic Oscillator 61.32 56.93

Price Performance

Historical Comparison
SHMD
NGNE

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: